Ad
Sunday, 31 May 2020
AstraZeneca-Merck Lynparza gets EMA's positive recommendation
Drugmakers AstraZeneca Plc and Merck & Co Inc said on Monday their blockbluster cancer drug, Lynparza, has received positive recommendation from the European Medicines Agency (EMA) as a maintenance treatment for a form of pancreatic cancer.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment